U.S. markets closed
  • S&P Futures

    3,926.75
    +4.25 (+0.11%)
     
  • Dow Futures

    31,989.00
    +73.00 (+0.23%)
     
  • Nasdaq Futures

    13,301.50
    -0.50 (-0.00%)
     
  • Russell 2000 Futures

    2,295.10
    +10.00 (+0.44%)
     
  • Crude Oil

    63.53
    +0.31 (+0.49%)
     
  • Gold

    1,798.60
    +0.70 (+0.04%)
     
  • Silver

    28.07
    +0.21 (+0.74%)
     
  • EUR/USD

    1.2167
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.3890
    +0.0270 (+1.98%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4137
    -0.0004 (-0.03%)
     
  • USD/JPY

    106.0340
    +0.1520 (+0.14%)
     
  • BTC-USD

    50,625.45
    +1,691.65 (+3.46%)
     
  • CMC Crypto 200

    1,011.32
    -3.60 (-0.35%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,162.46
    +490.76 (+1.65%)
     

Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW HAVEN, Conn., Feb. 23, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will host a conference call and webcast to report fourth quarter and full year 2020 financial results and provide a review of recent accomplishments and anticipated upcoming milestones, on Monday March 1, 2021 at 8:30 a.m. ET.

(PRNewsfoto/Biohaven Pharmaceutical Holding)
(PRNewsfoto/Biohaven Pharmaceutical Holding)

To access the call, please dial 877-407-9120 (domestic) or 412-902-1009 (international). The conference call webcast and accompanying slide presentation can be accessed through the "Investors" section of Biohaven's website at www.biohavenpharma.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the call will be made available for two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (domestic) or 201-612-7415 (international) with conference ID 13715754. An archived webcast will be available on Biohaven's website.

About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC® ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, and spinocerebellar ataxia; and myeloperoxidase (MPO) inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.

NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC.

Biohaven Contact:
Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-to-report-fourth-quarter-and-full-year-2020-financial-results-and-recent-business-developments-on-march-1-2021-301234050.html

SOURCE Biohaven Pharmaceutical Holding Company Ltd.